Medtronic's Resolute Integrity DES reaches Europe
This article was originally published in Clinica
Executive Summary
Medtronic has CE marked its Resolute Integrity drug-eluting stent (DES) for sale in Europe, and has launched the device in "European and other countries outside the US that recognise the CE mark". The Minneapolis, Minnesota firm says the device is "significantly more deliverable" than the market-leading stents. Resolute Integrity shares two elements of the original Resolute DES: the cytostatic antiproliferative drug zotarolimus and the highly biocompatible BioLinx polymer.